How Cape Bio Pharms Seeks Commercialise Biotech Development
How Cape Bio Pharms Seeks Commercialise Biotech Development. Cape Bio Pharms is an exciting new (ad)venture based in Cape Town, South Africa. The company is a spin-off company of the University of Cape Town aimed at commercialising the biotech developed by the Biopharming Research Unit (BRU) for the production of recombinant proteins in tobacco (actually a distant cousin of the tobacco plant).
The company’s product pipeline focuses on a wide range of research reagents such as antibodies, fusion proteins, peptides and enzymes. All are critical research tools for life scientists around the world in search of new drugs to treat the onslaught of human and animal disease. Its custom Protein Service offers life scientists the opportunity of ‘doing it in plants’.
Plant-based expressions allows Cape Bio Pharms to quickly and economically produce proof-of-concept trials from microgram to gram quantities. ‘Doing it in plants’ is an ethical alternative as it does not use animals in the making of its antibodies. The company’s team is a passionate group of postgraduates from multiple disciplines such as Molecular & Cell Biology, Medical Biochemistry and Human and Cell Biology. The team consists of a variety of skills and experiences that come together to make molecular magic. Whether they’re working on the science of building the business, they’re all behind its purpose of achieving Biosecurity for Africa.
Cape Bio Pharms regard all life scientists as part of one global research community, which it aims to serve. Cape Bio Pharms is positioned in the Western Cape surrounded by world class research institutions such as The University of Cape Town, Stellenbosch University, The University of The Western Cape and many others.
